Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 683 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Eczema Clear all
Completed No phase listed Observational

A Study to Evaluate CLn® BodyWash As Added Therapy in Eczema Patients

NCT01714245
View directory record Official record
Conditions
Eczema, Atopic Dermatitis
Interventions
Not listed
Lead sponsor
TopMD Skin Care, Inc.
Industry
Eligibility
6 Months to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 25, 2026, 4:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sweat and Gas Sensor for Healthy Skin and Atopic Dermatitis

NCT03874039
View directory record Official record
Conditions
Healthy Adults, Atopic Dermatitis, Wearables, Sweat Sensor, Gas Sensor
Interventions
Gas sensor, Sweat Sensor
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 25, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Results available

Evaluation of the Efficacy of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients

NCT03158012
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
Autologous Microbial Transplant
Biological
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 25, 2026, 4:40 PM EDT
Terminated No phase listed Observational

Asthma, Missed Immunizations, and Vitamin D Deficiency in Atopic Dermatitis

NCT01234909
View directory record Official record
Conditions
Atopic Dermatitis, Vitamin D Deficiency, Asthma
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 18 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 25, 2026, 4:40 PM EDT
Completed Phase 4 Interventional Results available

Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)

NCT00367016
View directory record Official record
Conditions
Asthma, Allergic Rhinitis, Atopic Dermatitis
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 25, 2026, 4:40 PM EDT
Terminated Phase 4 Interventional

Dupilumab De-escalation in Pediatric Atopic Dermatitis

NCT06116526
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab - Discontinuation, Dupilumab - Dose Reduction, Dupilumab - Standard Dose
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
1 Year to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 25, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

NCT03985943
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Placebo, Nemolizumab
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
57
States / cities
North Little Rock, Arkansas • Cerritos, California • Fountain Valley, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 25, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis

NCT03796676
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, PF-04965842, PF04965842
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 17 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
52
States / cities
Birmingham, Alabama • Madera, California • Mission Viejo, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 25, 2026, 4:40 PM EDT
Active, not recruiting Phase 2 Interventional

Seal, Stopping Eczema and Allergy Study

NCT03742414
View directory record Official record
Conditions
Eczema, Infantile, Eczema, Atopic Dermatitis Eczema, Atopic Dermatitis
Interventions
Tri-lipid skin barrier cream (Epiceram), Fluticasone propionate Cream 0.05%, Standard of Care
Combination Product · Other
Lead sponsor
Kari Nadeau, MD, PhD
Other
Eligibility
1 Week to 12 Weeks
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
Palo Alto, California • Denver, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 25, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

8-Week Atopic Dermatitis (AD) Treatment Study

NCT03386032
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
Investigational OTC Cream, 0.05% Desonide, Placebo Cream
Drug · Other
Lead sponsor
Procter and Gamble
Industry
Eligibility
12 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Raleigh, North Carolina • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 25, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Secukinumab for Treatment of Atopic Dermatitis

NCT02594098
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 25, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis

NCT02347176
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, Tralokinumab Dose 1, Tralokinumab Dose 2, Tralokinumab Dose 3
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
24
States / cities
Phoenix, Arizona • Rogers, Arkansas • Fremont, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 25, 2026, 4:40 PM EDT
Completed Phase 2 Interventional

Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT05158023
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo Comparator, ASLAN004
Drug · Biological
Lead sponsor
ASLAN Pharmaceuticals
Other
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
47
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Encino, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 25, 2026, 4:40 PM EDT
Recruiting Phase 2 Interventional

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

NCT07223697
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Afimkibart
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
7
States / cities
Los Angeles, California • Tampa, Florida • Alpharetta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 4:40 PM EDT
Recruiting Phase 4 Interventional

Dupixent and Narrowband UVB for Atopic Dermatitis

NCT05285839
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupixent
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 25, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

NCT02743871
View directory record Official record
Conditions
Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis
Interventions
PF-06817024, Placebo for PF-06817024
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
20
States / cities
Sacramento, California • New Haven, Connecticut • Shelton, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Oct 25, 2026, 4:40 PM EDT
Not yet recruiting Phase 4 Interventional

Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients

NCT06397781
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Skin Cleanser Combination No.1
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2031 – 2039
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 25, 2026, 4:40 PM EDT
Active, not recruiting Not applicable Interventional

A Clinical Trial to Evaluate the Effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in Adults With Eczema-Prone Skin

NCT07700745
View directory record Official record
Conditions
Eczema, Atopic Dermatitis, Eczema-Prone Skin
Interventions
Rejuvaskin Eczema Body Wash
Dietary Supplement
Lead sponsor
Rejuvaskin
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 25, 2026, 4:40 PM EDT
Completed Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis

NCT06790121
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Lunsekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
23
States / cities
Encino, California • Sacramento, California • Thousand Oaks, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 25, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis

NCT02975206
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
Serlopitant High Dose, Placebo Oral Tablet, Serlopitant Low Dose
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
13 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Anniston, Alabama • Birmingham, Alabama • Hoover, Alabama + 44 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 25, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Results available

Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)

NCT05450198
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
MK-6194, Placebo
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
North Little Rock, Arkansas • Miami, Florida • Miami Lakes, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 25, 2026, 4:40 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab

NCT04365387
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Nemolizumab, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 54 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
64
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 25, 2026, 4:40 PM EDT
Completed Phase 2 Interventional

A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis

NCT00703573
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
S-777469 400 mg, S-777469 800 mg, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
33
States / cities
Hot Springs, Arkansas • Los Angeles, California • Oceanside, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 25, 2026, 4:40 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Systems Biology of Early Atopy

NCT04798079
View directory record Official record
Conditions
Allergic Diseases, Food Allergy, Atopic Dermatitis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
0 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2032
U.S. locations
13
States / cities
Little Rock, Arkansas • Stanford, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 25, 2026, 4:40 PM EDT